SCHEMBL17349896

SCHEMBL17349896

CC(C)(C)C(=O)OCOC(=O)c1cccc2c1OB(O)[C@@H](NC(=O)c1ccc(Cl)cc1)C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCB P05771 1/20 0.40
▸ PRKCA P17252 1/20 0.40
▸ PRKCH P24723 1/20 0.40
▸ PRKCE Q02156 1/20 0.40
▸ PRKCD Q05655 1/20 0.40
▸ ELANE P08246 2/20 0.33
▸ PRTN3 P24158 2/20 0.33
▸ SSTR4 P31391 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ MIF P14174 1/20 0.32
▸ HTR4 Q13639 1/20 0.31
▸ PRMT5 O14744 2/20 0.31
▸ DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17349759 0.92 PRKCE (0.48) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349989 0.92 PRKCB (0.40) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349887 0.91 PRKCB (0.40) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349877 0.90 PRKCB (0.40) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349895 0.89 ALDH1A1 (0.37) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349901 0.89 PRKCB (0.36) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349899 0.88 ALDH1A1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL17349891 0.87 PRKCB (0.41) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337512 0.86 PRKCB (0.35) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337516 0.86 PRKCB (0.35) PRKCBPRKCAPRKCHPRKCEPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS SI, ALPI, GAA PRKCB 3762/4885PRKCA 3994/4885PRKCH 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback